We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Needle Biopsies as Accurate as Surgical Biopsies Detecting Breast Cancer

By HospiMedica International staff writers
Posted on 29 Dec 2009
Core needle biopsies for diagnosing breast cancer are nearly as accurate as a surgical biopsy but entail less risk, according to a new study.

Researchers at the ECRI (Plymouth Meeting, PA, USA) evidence-based practice center examined databases, including Medline and EMBASE, from 1990 to September 2009, for studies that compared core-needle biopsy diagnoses with open surgical diagnoses or clinical follow-up. More...
A total of 33 studies of stereotactic automated gun biopsy, 22 studies of stereotactic vacuum-assisted biopsy, 16 studies of ultrasonography (US)-guided automated gun biopsy, 7 studies of US-guided vacuum-assisted biopsy, and 5 studies of freehand automated gun biopsy that met the inclusion criteria were abstracted by one of three researchers, verified by the primary investigator, and the data were then synthesized.

The results of the analysis found low-strength evidence that core-needle biopsies conducted under stereotactic guidance with vacuum assistance distinguished between malignant and benign lesions with an accuracy that is similar to that of open surgical biopsy; US-guided biopsies were also very accurate. The risk of severe complications was found to be lower with core-needle biopsy than open surgical procedures. Moderate-strength evidence showed that women in whom breast cancer was initially diagnosed by core-needle biopsy were more likely than women with cancer initially diagnosed by open surgical biopsy to be treated with a single surgical procedure. The researchers concluded that stereotactic- and US-guided core-needle-biopsy procedures seem to be almost as accurate as open surgical biopsy, with lower complication rates. The study was published ahead of print on December 14, 2009, in the Annals of Internal Medicine.

"One challenge of providing appropriate care for patients is finding balance between the accuracy of a test or procedure and causing the least harm and burden to patients,” said Carolyn M. Clancy, M.D., director of the U.S. Agency for Healthcare Research and Quality (AHRQ, Rockville, MD, USA), who commissioned the research. "This report indicates that core-needle biopsy may strike that balance in many instances. Patients should continue to speak to their doctor when making important decisions about testing, and use all available information to make the decision that is right for them.”

Core-needle biopsy is a procedure usually performed under local anesthesia that involves removing small samples of breast tissue through a hollow core needle inserted through the skin. The suspicious lesion may be located by palpation or by imaging via stereotactic mammography, US, or magnetic resonance imaging (MRI). Multiple core-needle samples may be taken from the suspicious area. A variant on core-needle biopsy is vacuum-assisted biopsy. After locating the suspicious area, the probe of the device is inserted into the suspicious area; the device then uses vacuum suction to help remove tissue samples.

Related Links:

ECRI
U.S. Agency for Healthcare Research and Quality




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.